India Ministries Divided Over CL For BMS Sprycel Blood Cancer Drug
This article was originally published in PharmAsia News
Executive Summary
Two of India's ministries are divided over one's urging that a compulsory license be issued to allow a generic of Bristol-Myers Squibb's Sprycel (dasatinib) for treating chronic myeloid leukemia, a rare blood cancer.